Lori Raquel Hilden

Title: Lori Raquel Hilden: Pharmaceutical Inventor

Introduction

Lori Raquel Hilden is a woman inventor associated with Eli Lilly and Company in Indianapolis, Indiana. Her patent work concerns cocrystalline forms of FGFR3 inhibitors, an area of pharmaceutical research focused on potential treatments for diseases and disorders associated with FGFR3.

Latest Patents

Hilden is associated with 1 patent: “Cocrystalline Forms of FGFR3 Inhibitors.” The patent describes cocrystalline forms of FGFR3 inhibitors combined with gallic acid or nicotinamide coformers. It also covers characterizations and methods for making these forms, which are presented as potentially useful in treating or preventing conditions that can be addressed with an FGFR3 inhibitor.

Career Highlights

Hilden’s listed invention reflects work at the intersection of pharmaceutical formulation and therapeutic research. The patent focuses on developing and characterizing cocrystalline forms intended for potential medical applications.

Collaborations

Her listed coworkers include David Andrew Coates and Gislaine Kuminek. Their shared association with this patent connects their work to research on FGFR3 inhibitor cocrystals.

Conclusion

Lori Raquel Hilden’s patent activity at Eli Lilly and Company highlights her contribution to pharmaceutical research through cocrystalline forms of FGFR3 inhibitors and their potential therapeutic uses.